Agents for the Treatment of Glycosphingolipid Storage Disorders

E-ISSN： 1875-5453|2|3|331-338

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.2, Iss.3, 2001-09, pp. : 331-338

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Substrate reduction therapy for glycosphingolipid storage disorders

By Lachmann R.H. Platt F.M.

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 3, 2001-03 ,pp. : 455-466

Informa Healthcare

Access to resources Recommend Favorite

Treatment options for lysosomal storage disorders: developing insights

By van Gelder Carin M Vollebregt Audrey AM Plug Iris van der Ploeg Ans T Reuser Arnold JJ

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2281-2299

Informa Healthcare

Access to resources Recommend Favorite

Pharmacological small molecules for the treatment of lysosomal storage disorders

By Smid BE Aerts JMFG Boot RG Linthorst GE Hollak CEM

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1367-1379

Informa Healthcare

Access to resources Recommend Favorite

Treatment of Lysosomal Storage Disorders: Progress with Enzyme Replacement Therapy

By Rohrbach Marianne Clarke Joe T.R.

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2697-2716

Adis International

Access to resources Recommend Favorite

A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity

By Fan J.-Q.

Trends in Pharmacological Sciences, Vol. 24, Iss. 7, 2003-07 ,pp. : 355-360

Elsevier

Access to resources Recommend Favorite